{'fraction_non_alphanumeric': 0.026837806301050177, 'fraction_numerical': 0.0011668611435239206, 'mean_word_length': 5.703125, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Prevention and treatment of NSAIDs-induced small intestinal lesions].

Recently, the serious problem of non-steroidal anti-inflammatory drugs(NSAIDs)-induced small intestinal damage has become a topic of great interest to gastroenterologists, since capsule endoscopy and double-balloon enteroscopy are available for the detection of small intestinal lesions. We found some of mucoprotective agents, PPIs and H2-blockers prevented NSAIDs-induced small intestinal lesions in rat. The clinical trials suggested that some of mucoprotective agents and prostaglandin analog, not acid suppressants inhibited small intestinal lesions in healthy volunteers. Considering the cost benefit and the load of patients, we hope that one drug can prevent NSAIDs-induced lesions from esophagus to small intestines. We should use mucoprotective drugs well for these diseases.